Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion NV    OXUR   BE0003846632

OXURION NV

(OXUR)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
3.035(c) 3.04(c) 3.05(c) 2.975(c) 3.02 Last
16 831 15 553 12 802 71 413 20 819 Volume
-1.78% +0.16% +0.33% -2.46% +1.51% Change
More quotes
Financials
Sales 2020 - - -
Net income 2020 -42,1 M -47,7 M -47,7 M
Net Debt 2020 - - -
P/E ratio 2020 -3,72x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -67,1 M -76,0 M -76,0 M
Net Debt 2021 - - -
P/E ratio 2021 -2,89x
Yield 2021 -
Capitalization 114 M 129 M 129 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 77
Free-Float 79,5%
More Financials
Company
Oxurion NV specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (96.8%); - royalties (3.2%). 
More about the company
Latest news on OXURION NV
05/07OXURION NV : 1st quarter results
CO
04/03OXURION NV : Ordinary general shareholder meeting
CO
03/30OXURION : Investigational Drug Vericiguat Significantly Reduced the Risk of the ..
AQ
03/28OXURION : COVID-19 Statement
PU
03/12OXURION NV : Annual results
CO
02/10Oxurion NV - Expert Presentation of Positive Topline Data from a Phase 1 Stud..
AQ
02/06Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687..
AQ
02/05Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687..
AQ
2019OXURION : Business Update - Q3 2019
AQ
2019OXURION : 3rd quarter results
CO
2019OXURION : to Provide Business and Clinical Update at Upcoming American Academy o..
AQ
2019OXURION : Business Update - H1 2019
AQ
2019OXURION : to make a late-breaker presentation of topline THR-149 Phase 1 clinica..
AQ
2019OXURION : Half-year report
CO
2019OXURION : ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipelin..
GL
More news
News in other languages on OXURION NV
03/30OXURION : Investigational Drug Vericiguat Significantly Reduced the Risk of the ..
03/28OXURION : COVID-19 Statement
02/10Oxurion NV - Expert Presentation of Positive Topline Data from a Phase 1 Stud..
02/06Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687..
02/05Oxurion NV - Additional Topline Data from Positive Phase 1 Trial with THR-687..
More news
Chart OXURION NV
Duration : Period :
Oxurion NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION NV
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 7,50 €
Last Close Price 2,98 €
Spread / Highest target 303%
Spread / Average Target 152%
Spread / Lowest Target 0,84%
EPS Revisions
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Independent Non-Executive Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
Jean Feyen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
OXURION NV0.85%129
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344